Laval, QC – June 12, 2025 – Corealis Pharma is proud to announce its membership in the CQDM network, an initiative aimed at strengthening collaboration within the biopharmaceutical industry and accelerating innovation for the development of new medicines for patients.
As a member, Corealis Pharma joins a dynamic ecosystem that fosters networking, knowledge sharing, and access to key resources for life sciences companies across Quebec and Canada. This membership aligns with Corealis Pharma’s mission to support and propel Canadian and Quebec-based innovators by providing them with its pharmaceutical development expertise.
David Leroux-Petersen, Chief Executive Officer of Corealis Pharma, stated: “Innovation and collaboration are at the heart of our approach at Corealis Pharma. By joining the CQDM network, we strengthen our commitment to the Quebec and Canadian biopharmaceutical ecosystem by supporting local innovators. Together, we can accelerate the development of new therapies and maximize their impact on patient health.”
“CQDM is delighted to welcome Corealis Pharma as a Network member. This collaboration reflects a shared desire to support biopharmaceutical innovation in Quebec by leveraging complementary expertise. As a leader in pharmaceutical formulation and clinical batch manufacturing, Corealis Pharma brings tangible added value to our collaborative ecosystem. Together, we promote the development of innovative therapeutic solutions, accelerating their passage from the laboratory to the patient, for the benefit of the health and economy of Quebec and Canada,” says Véronique Dugas, President and CEO of CQDM.
Together, Corealis Pharma and CQDM are dedicated to creating an environment conducive to discovery and the development of innovative solutions to improve patient access to new medicines across Quebec and beyond.
About CQDM
Biopharma Innovation Facilitator
CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website www.cqdm.org and join us on Twitter/X @CQDM_Canada and LinkedIn.
About Corealis Pharma
Corealis Pharma is a premier CDMO specializing in formulation development and the manufacturing of solid oral dosage forms for the pharmaceutical and biotech industries. Recognized for its technical excellence, agility, and client-centric approach, Corealis provides a comprehensive range of services, from early-stage formulation to GMP clinical trial material manufacturing.
For inquiries, please contact:
Patrick Frankham, VP, Business Development Corealis Pharma Inc.
Email: patrick.frankham@corealispharma.com
Phone: +1 (450) 973-7505
www.corealispharma.com
Contact Corealis
Corealis’ experts are ready to answer any queries about the company’s oral solid dose offering, including its development and manufacturing capabilities.
